Psoriasis Drug Studied for Slowing Inflammation in Type 1 Diabetes

Researchers have identified a potential method for slowing the progression of type 1 diabetes by using a drug currently approved for psoriasis treatment to target inflammation. The research indicates that the drug may lessen the effects of inflammation associated with the disease. The study involved examining the impact of a psoriasis drug on the inflammatory processes involved in type 1 diabetes. Scientists focused on the drug’s ability to modulate the immune response and potentially protect insulin-producing cells in the pancreas. The findings suggest that this approach may offer a way to intervene in the disease’s progression.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Related posts:

Study Reveals Cognitive Decline Linked to Low-Normal Vitamin B12 Levels Roger Perlmutter’s New Biotech Startup Secures $350 Million in Funding Breakthrough in Cancer Vaccine Development Enhances Effectiveness and Reach Anne Wojcicki’s Bold Move to Reclaim 23andMe Sparks Debate in Biotech Industry

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後